Ocugen's Top Brass to Present at 3 Major Conferences
Ocugen, a leading biotech company specializing in gene therapies for blindness, has announced its participation in three major conferences. The company's top executives, including Dr. Shankar Musunuri and Abhi Gupta, will present and engage in panel discussions at these events.
Dr. Musunuri, Ocugen's Chairman, CEO, and Co-founder, will take the stage as a featured panelist at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025. He will also share his insights at the 2025 Maxim Growth Summit on October 22, 2025.
Gupta, Ocugen's Executive Vice President of Commercial and Business Development, will deliver a company update at the Cell & Gene Meeting on the Mesa on October 6, 2025. Both leaders will conduct one-on-one meetings at these conferences to highlight Ocugen's business and clinical development strategy.
Ocugen's modifier gene therapy platform has the potential to address significant unmet medical needs for large patient populations affected by blindness diseases. The company aims to advance towards its goal of submitting three Biologics License Applications (BLAs) in the next three years.
Ocugen's prominent presence at these conferences underscores its commitment to advancing gene therapies for blindness diseases. The company's leadership team looks forward to engaging with industry professionals and sharing Ocugen's innovative approach to treating inherited retinal diseases and other blindness conditions.
